cyrilzakka/clinical-trials huggingface dataset:
The Treatment Effect for Asymptomatic Common Bile Duct Stone

This study is prospective, multicenter study for identify the characteristics of asymptomatic common bile duct stones and effectiveness of treatment.

There is no conflcts for treatment of symptomatic common bile duct stone. As more imaging examination such as healthy screening, more asymptomatic common bile duct stone patients are found. Current guideline for aymptomatic common bile duct stone is removal using endoscopic retrograde cholangiopancreatography. However, the previous studies that support this guideline included patients who just underwent cholecystectomy and were diagnosed as common bile duct stone. There is no prospective study for identify the treatment effectiveness of common bile duct stone removal in asymptomatic patients who are dignosed in healthy screening. Therefore, we are going to find the effectiveness of common bile duct stone removal by comparing questionnarie before and after removal of common bile duct stone in asymptomatic and incidentally found common bile duct stone patients. In addition, we are going to follow up patients who do not want to undergo common bile duct stone removal and find the rate of cholangitis risk. We also want to identify extact complication rate for endoscopic retrograde pancreatocholangiographic procedures in asymptomatic common bile duct stone.

Eligibility Criteria:
Inclusion Criteria:

* diagnosed as common bile duct stone by image modality examination
* agreement for this study enrollment

Exclusion Criteria:

* no definite common bile duct stone by image modality examination
* symptomatic patients who complain with fever/abdominal pain that compatible with common bile duct stone related symptom
* previously diagnosed as pancreatobiliary malignancy
* previously treated by endoscopic or percutaneous treatment for bile duct stones
* severe cardio or pulmonary disease
* pregnancy or possibility of pregnancy
* who do not agree with study enrollment
The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of cytokine-induced killer cell (CIK) plus S-1 and Bevacizumab vs S-1 and Bevacizumab as Maintenance Treatment for patients with advanced colorectal cancer.

1200 patients with stage Ⅳ colorectal cancer,who had received surgery and chemotherapy,will be randomly divided into group A（receive CIK plus S-1 and Bevacizumab ) or group B（just receive S-1 and Bevacizumab),and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of CIK treatment (every 1 year) and Apatinib (continuous).Patients in group B will receive only S-1 and Bevacizumab (continuous) .

Eligibility Criteria:
Inclusion Criteria:

* Patients who can accept curative operations 18-70 years old
* Histologically confirmed with colorectal cancer at stage Ⅳ
* Patients who can accept oral drugs;
* Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1.

Exclusion Criteria:

* Hemoglobin\<8.0 g/dL,White blood cell \<3 X 10\^9/L;Platelet count \<75 X 10\^9/L; alanine aminotransferase, glutamic-oxalacetic transaminase, blood urine nitrogen and creatinine more than normal limits on 3.0 times
* Known or suspected allergy to the investigational agent or any agent given in association with this trial
* Pregnant or lactating patients
* Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection
* Patients who are suffering from serious autoimmune disease
* Patients who had used long time or are using immunosuppressant
* Patients who had active infection
* Patients who are suffering from serious organ dysfunction
* Patients who are suffering from other cancer
* Other situations that the researchers considered unsuitable for this study.
Risk Factor Association of Musculoskeletal Injuries Among University Students

This research will be conducted to identify the factors that increase the risk of musculoskeletal injuries in college students, Hypothesis: Demographic, anthropometric, postural, sleep quality and physical activity characteristics significantly predicted musculoskeletal injury.

An important public health issues for young people, particularly university students is musculoskeletal injuries.The wound may cause excruciating agony, functional limitations,and decreased quality of life (Almeida et al.,2013). musculoskeletal injuries have a complicated etiology, with important roles played by demographics, anthropometric, psychological,postural, sleep quality, and physical activity variable.To create focused preventives and intervention measures, it is essential to understand the risk factor of musculoskeletal injuries among university students.

Questionnaire has been extensively utilized to asses postural risk factor for musculoskeletal illness such as low back pain. Musculoskeletal injuries have been linked to possible risk factors related to sleep quality, physical activity in previous study. However it is still unclear how these factor interact in a complex way and how that affects the likelihood of musculoskeletal injury.

By examining the association between demographics, anthropometric, phycological, postural, sleep quality and physical activity in university students,this study seeks to fill this vacuum in the literature.The results of this study will offer insightfull information that will help to guide the creation of focused preventives and intervention for this demographics.

The date will be collected through the use of structure questionnaire the survey will ask questions on demographics data, psychological aspects, posture, sleep patterns, and level of physical activity and the participants will be required to complete the 9-test screening Battery for musculoskeletal damage.

The following resources will be utilized to gather information on various aspects of musculoskeletal injuries.

Age, gender, height, weight, and body mass index (BMI) General health questionnaire (GHQ) Nordic musculoskeletal questionnaire for posture evaluation (NMQ) Pittsburgh sleep quality index is used to evaluate sleep quality (pSQI) International physical activity questionnaire for measuring physical activity (IPAQ) Screening for musculoskeletal injuries:9-test MSK injury screening Battery

Eligibility Criteria:
Inclusion Criteria:

* Undergraduate students
* ages of 18 and 25.

Exclusion Criteria:

* Graduate students
* younger than 18 or older than 25
* who refuse to take part in the study will all be disqualified.
Effect of Trunk Support on Academic Engagement of Children With Severe Disability

This study evaluates the effect of optimizing trunk support based on segmental principles of trunk control, on academic engagement of children in academic settings.

Head and trunk posture control are foundational skills, impacting vision, communication, swallowing, eating, reaching, and gait. Vision, communication and upper extremity skills are critical for participation in educational settings. From an academic point of view, participants with poor trunk stability have difficulties staying erect and keeping their head and trunk steady. This interferes with concentration, reduces ability and aptitude for learning and can lead to fatigue and reduced time on task. Examination of the effect of optimal trunk support may yield critical information regarding academic engagement in children with moderate to severe disability.

The investigators propose to facilitate use of a segmental approach by physical and occupational therapists in educational settings. Activities will include identifying level of trunk control and applying segmental principles to adapt participant's positioning devices for optimal function.

Eligibility Criteria:
Inclusion Criteria:

* Referral from physical, occupational or speech therapist working in Hartford Public School District or Connecticut Birth to Three,
* Segmental deficit in trunk control as measured by Segmental Assessment of Trunk Control
* parent or guardian consent that includes permission for video data collection and sharing of IEP (individualized education plan) or IFSP (individualized family support plan).

Exclusion Criteria:

* pain that interferes with positioning,
* impending surgery that will result in extended absence from school
Task Atlas: Study to Develop a Task Atlas of Brain Recruitment During a Digital Game-based Program

Healthy volunteers ages 25-40 from the general US population who meet the eligibility criteria and are enrolled will (a) play Lumosity games at least 20 times each in under 60 days and (b) then complete one session of task-based functional magnetic resonance imaging (fMRI) while playing Lumosity games.


Eligibility Criteria:
Inclusion Criteria:

* Subjects 25-40 years of age.
* Ability to understand and speak English, follow written and verbal instructions (English), and give informed consent (English), as assessed by the PI or project manager.
* Ability to comply with all the testing and study requirements, including the ability to independently complete daily, online Lumosity games on a reliable, internet-connected device.
* Geographical location within 100 miles of the study imaging center.

Exclusion Criteria:

* Current, controlled (requiring treatment) or uncontrolled psychiatric diagnosis, including but not limited to posttraumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, attention- deficit/hyperactivity disorder, or other symptomatic manifestations that in the opinion of the PI may confound study data/assessments.
* Current, controlled (requiring treatment) or uncontrolled neurological diagnosis, including but not limited to Alzheimer's Disease, other dementias, mild cognitive impairment, Huntington's Disease, Parkinson's Disease, multiple sclerosis, stroke, epilepsy, aphasia, or other condition that in the opinion of the PI may confound study data/assessments.
* Any other medical condition in the last 90 days that in the opinion of the PI may confound study data/assessments.
* Has been under the care of a caretaker or has not been living independently in the last 90 days.
* In the last three years has used online brain training programs (e.g., BrainHQ, Lumosity, Peak) for more than two weeks continuously.
* Known sensitivity (such as headaches, dizziness, nausea) to bright, stimulating video displays.
* History of seizures (excluding febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder and photo-sensitive epilepsy.
* Visual acuity that cannot be corrected that prevents or negatively impacts computer activity.
* Pregnancy, or strong likelihood of pregnancy.
* Left-handed or ambidextrous.
* Unwillingness or inability to comply with imaging safety protocols. Inability includes but is not limited to metal implants or exposure to shrapnel.
* Any other condition that in the opinion of the PI may confound study data.
To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase

All consecutive ACLF (Acute on Chronic Liver failure) patients presenting to the institute of liver and biliary sciences, irrespective of the etiology , who have survived the acute phase (i.e. 90 days of onset of the acute on chronic liver failure) and who are willing to participate in the study would be enrolled. After performing baseline biochemical tests, patients will undergo transjugular liver biopsy (TJLB), HVPG (Hepatic Venous Pressure Gradient), Circulating CD34 cells, Bone marrow aspiration and biopsy (Histopathological and immunohistochemical examination will be done).


Eligibility Criteria:
Inclusion Criteria:

* Subjects aged 18-65 years
* All patients who were known to have ACLF and have survived 3 months of the onset of acute event
* Patients willing to participate in the study

Exclusion Criteria:

* Presence of AKI (Acute Kidney Injury)
* Active sepsis (Blood/ urine culture positive, SBP (Spontaneous bacterial Peritonitis, LRTI (lower Respiratory Tract infection)
* Sickle cell anemia
* HepatoCellular Carcinoma
* Hematological malignancies
* Multi organ failure
* Grade 3/ 4 HE (Hepatic Encephalopathy)
* HIV seropositivity
* Pregnancy
* Patients being taken up for transplant
* Refusal to participate in the study
Characterization of Artifacts in the BIS™ EEG Signals in General Anesthesia Patients in Operating Room

This is an observational non-invasive study which aims to collect data from patients under general anesthesia in the operating room; this data will then be used for characterization and detection of artifacts that affect the EEG signal.

This observational, non-invasive study will be performed in order to identify the effects of physiological and environmental artifacts on the EEG raw data collected by the BIS™. This study will include 100 screened subjects (not more than 60 valid cases) and will take place in the Department of Anesthesiology at Rambam Health Care Campus. During the study, raw data from the BIS™ will be recorded simultaneously with EMG, EOG and ECG in order to diagnose their effects on the EEG signals as recorded by the BIS™. The raw data will be considered as the main parameters of the study. Additionally, a study coordinator will stay in the operating room during the surgery and will indicate the following parameters -

1. Medical treatment (drug, dosage and time)
2. Changes in hypnotic state (state, time)
3. Any activity that may affect the EEG signals (i.e. electrical and mechanical artifacts from medical devices)
4. Any activity that deviates from the clinical procedure
5. Any adverse events or unusual outcomes From the list above, parameters a, c and d will also be considered as main parameters and parameters and parameters d and e will be considered as safety parameters.

If applicable, BIS™ will be recorded after the surgery, at the PACU, for part of time the subject will be at the PACU or until the subject will be released from the department. The study coordinator/investigator will perform POD assessment at that time. The subject will be considered as valid case even if the data from the recovery room is missing.

Demographic details and medical history will be copied by the study coordinator from the subjects' medical records.

Eligibility Criteria:
Inclusion Criteria:

* Men and Women
* Age \>18
* Ability and willingness to participate in the study and sign informed consent form
* Patients that will undergo elective surgery under general anesthesia.

Exclusion Criteria:

* Pregnant women
* Disability or unwillingness to undergo EEG/EMG/ECG measurement
* Subjects with known or suspected sensitivity to adhesive bandage
* Subjects who have sustained CVA or severe head trauma in the last 10 years.
* Subjects with known or suspected electroencephalograph abnormality (e.g. epilepsy or scarring)
* soldiers
* prisoners
Efficacy and Safety of Silfamin for Common Cold

This is a 2-arm, prospective, randomized, double-blind, placebo-controlled, and three-days-treatment clinical study comparing the efficacy and safety of Silfamin at a dose of 2 tablets@150 mg twice daily in subjects with common cold.

There will be 2 groups of treatment; each group will consist of 30 subjects receiving the following regimens for three days:

Treatment I : 2 tablets of Silfamin 150 mg 2 times daily Treatment II : 2 tablets of Placebo 2 times daily

Eligible subjects will be evaluated for treatment efficacy at 0 hours (just before drug administration), 1 and 2 hours after the first dose. For the next doses, subject will perform a self-assessment for treatment efficacy at 1 and 2 hours after every dosing, and record it in subject's diary.

Eligibility Criteria:
Inclusion Criteria:

* Otherwise healthy (by anamnesis) men or women aged 18 to 60 years with mild or moderate common cold with or without sore throat (Common cold Score of 1 or 2)
* Willing to participate in the study by signing the informed consent

Exclusion Criteria:

* Body temperature of \> 37.3˚C and/or refuse to follow health protocol for COVID-19
* Known hypersensitivity to herbal drugs containing Nigella sativa and/or Phaleria macrocarpa
* Pregnant or lactating women
* Have received any analgesic, anti-inflammatory or other common cold preparation within the past 24 hours
* Presence of vomiting or diarrhea within the past 24 hours and still ongoing at the start of study
* Severe illness, e.g. severe hypertension (\> 160/100 mmHg)
A Study of the Newly Formulated Tylenol Tablet (Acetaminophen) to the Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy Participants

The purpose of this study is to evaluate the bioequivalence of the newly formulated Tylenol tablet (acetaminophen 650 mg) with respect to the Tylenol 8 Hour (H) Extended Release (ER) tablet (acetaminophen 650 mg) in healthy participants under fasting conditions.


Eligibility Criteria:
Inclusion Criteria:

* Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. This determination must be recorded in the participant's source documents
* Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel including liver enzymes, other specific tests, hematology, urinalysis or breathing alcohol test are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
* Blood pressure (after the participant is sitting for 5 minutes) between 90 and 140 millimeters of Mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic
* Have no history of psychiatric disorder within the 5 years prior to the screening
* Have no history of gastrointestinal resection that may affect drug absorption

Exclusion Criteria:

* History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency (creatinine clearance below 60 milliliter per minute \[mL/min\]), thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
* Clinically significant abnormal physical examination, vital signs, or 12 lead ECG at screening as deemed appropriate by the investigator
* Known allergies, hypersensitivity, or intolerance to acetaminophen or its excipients
* History of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)
* Taken any disallowed therapies as noted in local prescribing information, concomitant therapy before the planned first dose of study drug
Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome

The purpose of this study is to compare the efficacy and safety of T2762 versus Optive® in the treatment of moderate to severe Dry Eye Syndrome.


Eligibility Criteria:
Inclusion Criteria:

* Signed and dated informed consent.
* Male or female aged ≥ 18 years old.
* Diagnosis of moderate to severe dry eye syndrome

Exclusion Criteria:

* Pregnancy, lactation.
* Childbearing potential woman who is not using a reliable method of contraception and is not surgically sterilised.
* Inability of patient to understand the study procedures and thus inability to give informed consent.
* Non-compliant patient
* Participation in another clinical study at the same time as the present study.
* Participation to the present study during the exclusion period of another clinical study.
* Already included once in this study.
* Ward of court.
* Patient not covered by government health care scheme
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.

This study consists of the following Periods:

* Initial Treatment Period from Week 0 to Week 16
* Maintenance Treatment Period from Week 16 to Week 48
* Open-label Extension Treatment Period (96 weeks)
* Safety Follow-Up (10 weeks)

Eligibility Criteria:
Inclusion Criteria:

* Provided informed consent
* Adult men or women \>= 18 years
* Chronic plaque psoriasis for at least 6 months
* Baseline psoriasis activity and severity index \>= 12 and body surface area \>= 10 % and Physician's Global Assessments score \>= 3
* Candidate for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy
* Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

* Erythrodermic, guttate, generalized pustular form of psoriasis
* History of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in the protocol
* Congestive heart failure
* History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease
* Concurrent malignancy or a history of malignancy as described in the protocol
* History of, or suspected, demyelinating disease of the central nervous system (e.g., multiple sclerosis or optic neuritis)
* Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 5 months following last dose of study drug in the UK, Czech Republic, Germany, and France, and within 3 months for all other countries. Male subjects who are planning a partner pregnancy during the study or within 5 months following the last dose in France and within 10 weeks in all other countries
* Any other condition which, in the Investigator's judgment, would make the subject unsuitable for participation in the study
* Other protocol-defined exclusion criteria may apply
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment.

Original tumor slides will be collected to identify tumor markers that may predict responses to treatment. Blood samples will be obtained prior to treatment with IL-2.

Eligibility Criteria:
Inclusion Criteria:

* Malignant melanoma that is metastatic or unresectable
* Eligible to receive high-dose IL-2
* Tissue block available with adequate tumor to perform RNA extraction and DASL analysis

Exclusion Criteria:

* Prior immunotherapy for unresectable or metastatic disease
* Untreated brain metastases, leptomeningeal disease, or seizure disorder